Annie Mcguire Sells 3,254 Shares of Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. (NASDAQ:VCYT) EVP Annie Mcguire sold 3,254 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $43.09, for a total value of $140,214.86. Following the completion of the sale, the executive vice president directly owned 131,160 shares in the company, valued at approximately $5,651,684.40. The trade was a 2.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Veracyte Stock Down 4.8%

NASDAQ:VCYT opened at $42.53 on Friday. Veracyte, Inc. has a 52 week low of $29.45 and a 52 week high of $60.91. The stock’s fifty day moving average is $50.64 and its two-hundred day moving average is $43.12. The stock has a market capitalization of $3.42 billion, a price-to-earnings ratio of 30.16 and a beta of 1.93.

Veracyte (NASDAQ:VCYT) last issued its quarterly earnings data on Thursday, July 30th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. The business had revenue of $150.32 million during the quarter, compared to analysts’ expectations of $144.59 million. Veracyte had a return on equity of 9.26% and a net margin of 20.37%.The company’s revenue was up 15.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.44 earnings per share. On average, sell-side analysts expect that Veracyte, Inc. will post 1.32 EPS for the current fiscal year.

Key Stories Impacting Veracyte

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Institutional ownership trends remain supportive. Bank of America, Royal Bank of Canada and William Blair increased their positions, while Summit Creek Advisors and Deutsche Bank initiated new stakes. Analysts maintain a “Moderate Buy” consensus with an average price target of $54.33, above recent trading levels. Veracyte insider trading and institutional ownership report
• Neutral Sentiment: Veracyte’s most recent reported quarter showed earnings of $0.54 per share versus the $0.41 consensus estimate, while revenue rose 15.5% year over year to $150.32 million. These results provide a fundamental backdrop of continued growth, although they are not new developments in the latest disclosures.
• Negative Sentiment: EVP Annie McGuire sold 3,254 shares for approximately $140,215, CFO Rebecca Chambers sold 3,652 shares for about $157,401, and insider Phillip Febbo sold 13,110 shares valued at roughly $564,386. Each transaction was executed through a 10b5-1 plan to cover taxes, and the sellers retained substantial positions, limiting the signal that management is broadly abandoning the stock. Veracyte executive stock sale filing
• Negative Sentiment: Director Muna Bhanji separately sold 1,864 shares for approximately $80,096, reducing her position by 4.18%. The sale was also pre-arranged, but the cluster of insider transactions may reinforce short-term caution among investors. Muna Bhanji Veracyte stock sale

Hedge Funds Weigh In On Veracyte

Several hedge funds and other institutional investors have recently made changes to their positions in VCYT. Corient Private Wealth LP grew its position in shares of Veracyte by 26.9% during the second quarter. Corient Private Wealth LP now owns 162,021 shares of the biotechnology company’s stock worth $9,515,000 after buying an additional 34,299 shares in the last quarter. Amundi raised its holdings in Veracyte by 92.2% in the second quarter. Amundi now owns 23,305 shares of the biotechnology company’s stock valued at $1,369,000 after acquiring an additional 11,181 shares in the last quarter. HighTower Advisors LLC purchased a new position in Veracyte in the second quarter worth approximately $439,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Veracyte in the second quarter worth approximately $719,000. Finally, California State Teachers Retirement System grew its holdings in Veracyte by 5,665.2% during the 2nd quarter. California State Teachers Retirement System now owns 5,363,282 shares of the biotechnology company’s stock worth $314,986,000 after acquiring an additional 5,270,253 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Morgan Stanley reduced their price target on shares of Veracyte from $47.00 to $44.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 4th. Weiss Ratings cut shares of Veracyte from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, August 24th. Wolfe Research initiated coverage on shares of Veracyte in a report on Tuesday, June 2nd. They set an “outperform” rating and a $55.00 target price on the stock. Wall Street Zen upgraded shares of Veracyte from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Finally, Canaccord Genuity Group dropped their price target on shares of Veracyte from $60.00 to $50.00 and set a “hold” rating for the company in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.33.

About Veracyte

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.